A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A

PHASE3CompletedINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

September 28, 2021

Primary Completion Date

March 18, 2024

Study Completion Date

March 18, 2024

Conditions
Charcot-Marie-Tooth Type 1A
Interventions
DRUG

PXT3003

Patients will be administered PXT3003 twice daily (bid) at 10mL.

DRUG

PXT3003 placebo

Patients will be administered PXT3003 placebo twice daily (bid) at 10mL.

Trial Locations (25)

Unknown

Peking University Third Hospital, Beijing

Xuanwu Hospital Capital Medical University, Beijing

The First Bethune Hospital of Jilin University, Changchun

The Third Xiangya Hospital of Central South University, Changsha

The First Affiliated Hospital of Fujian Medical University, Fuzhou

Nanfang Hospital Southern Medical University, Guangzhou

The First Affiliated Hospital,Sun Yat-sen University, Guangzhou

The Affiliated Hospital of Guizhou Medical University, Guiyang

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

The First Affiliated Hospital of Harbin Medical University, Harbin

The First Affiliated Hospital of Anhui Medical University, Hefei

Inner Mongolia People's Hospital, Hohhot

Qilu Hospital of Shandong University, Jinan

The Second Affiliated Hospital of Nanchang University, Nanchang

The Affiliated Hospital of Nanjing University Medical School, Nanjing

Zhongda Hospital Southeast University, Nanjing

Qilu Hospital of Shandong University(Qingdao), Qingdao

Shanghai Jiaotong University School of Medicine Ruijin Hospital, Shanghai

The First Hospital of China Medical University, Shenyang

The Second Hospital of Hebei Medical University, Shijiazhuang

The First Affiliated Hospital of Soochow University, Suzhou

Renmin Hospital of Wuhan University(Hubei General Hospital), Wuhan

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

Henan Provincial People's Hospital, Zhengzhou

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

Tasly GeneNet Pharmaceuticals Co., Ltd

INDUSTRY

NCT05092841 - A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A | Biotech Hunter | Biotech Hunter